B+
Bull case
25%
Probability
Target price
$7.50
+159.5% vs current
RCKT
RocketCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.60
+59.2% vs current
B-
Bear case
30%
Probability
Target price
$2.20
-23.9% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Lean neutral-to-cautiously constructive. Primary-source evidence improved with KRESLADI approval and PRV optionality, but the deterministic prior is neutral and the remaining thesis still depends heavily on a few binary biotech milestones rather than a broad operating base. This looks more like a monitoring name than a high-conviction re-rating call.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystPriority review voucher monetization after KRESLADI approvalHigh impact
The March 27, 2026 8-K says FDA approved KRESLADI for pediatric severe LAD-I and granted Rocket a Rare Pediatric Disease PRV, with management stating it intends to evaluate strategic monetization options to enhance financial flexibility [#8-K-2026-03-27]. A clean PRV sale could extend runway beyond the 2Q27 funding outlook in the 10-K.
2026-09-30eventDanon Phase 2 update after next three patientsHigh impact
The 2026-02-26 10-K says RP-A501 dosing resumed after the prior hold, six Phase 2 patients have been treated, and further updates are expected following review of data from the next three patients [#10-K-2026-02-26]. This is the highest-impact pipeline swing factor because it tests whether the recalibrated regimen can preserve efficacy while avoiding the 2025 safety setback.
2026-12-31catalystRP-A601 PKP2-ACM enrollment and development-path clarityHigh impact
The 2026-02-26 10-K says RP-A601 Phase 1 remains open and actively enrolling, three patients had been treated, and Rocket is working with FDA on alignment for a potential pivotal Phase 2 design [#10-K-2026-02-26]. Additional biology or regulatory clarity would matter because cardiac AAV programs are the main longer-duration upside after LAD-I approval.
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology